Literature DB >> 9223485

The VP16 paradox: herpes simplex virus VP16 contains a long-range activation domain but within the natural multiprotein complex activates only from promoter-proximal positions.

M Hagmann1, O Georgiev, W Schaffner.   

Abstract

Removal of core promoter elements like the TATA box converts several regulatory upstream regions of viral and cellular genes into classical enhancers, i.e., cis-regulatory elements capable of activating transcription over long distances in an orientation-independent manner. This is not the case with herpes simplex virus (HSV) immediate-early gene promoters, which are strongly induced by the viral transactivator VP16 (Vmw65, alphaTIF, ICP25) complexed with the cellular factors Oct-1 and HCF. Here we report that the VP16 complex can readily bring about strong activation from a promoter-proximal position but fails to induce transcription from a distal downstream enhancer position. This is in striking contrast to results obtained with GAL fusion proteins: in this context, the C-terminal "general" activation domain of VP16 activates transcription to high levels over long distances. Thus, this paradoxical behavior suggests that the VP16 activation domain is not accessible to the transcription machinery when the VP16-Oct-1-HCF complex is bound in a remote position. Only upon specific interactions in a promoter-proximal position, perhaps with the basal transcription factors, can transcription be strongly induced. In agreement with such a proposed mechanism, VP16 proteins to which a heterologous general activation domain has been added strongly activate transcription from a downstream position. The biological role of this unexpected and sophisticated mechanism is most probably a limitation of the VP16 activity to the associated immediate-early genes, without undesired long-range effects on other viral promoters within the tightly packed HSV genome.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9223485      PMCID: PMC191851     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  94 in total

1.  Differential positive control by Oct-1 and Oct-2: activation of a transcriptionally silent motif through Oct-1 and VP16 corecruitment.

Authors:  M A Cleary; S Stern; M Tanaka; W Herr
Journal:  Genes Dev       Date:  1993-01       Impact factor: 11.361

Review 2.  Structure(?) and function of acidic transcription activators.

Authors:  S Hahn
Journal:  Cell       Date:  1993-02-26       Impact factor: 41.582

3.  Interaction between an acidic activator and transcription factor TFIIB is required for transcriptional activation.

Authors:  S G Roberts; I Ha; E Maldonado; D Reinberg; M R Green
Journal:  Nature       Date:  1993-06-24       Impact factor: 49.962

4.  Transcriptional activation modulated by homopolymeric glutamine and proline stretches.

Authors:  H P Gerber; K Seipel; O Georgiev; M Höfferer; M Hug; S Rusconi; W Schaffner
Journal:  Science       Date:  1994-02-11       Impact factor: 47.728

5.  The VP16 accessory protein HCF is a family of polypeptides processed from a large precursor protein.

Authors:  A C Wilson; K LaMarco; M G Peterson; W Herr
Journal:  Cell       Date:  1993-07-16       Impact factor: 41.582

6.  Specific transcriptional activation in vitro by the herpes simplex virus protein VP16.

Authors:  D N Arnosti; C M Preston; M Hagmann; W Schaffner; R G Hope; G Laughlan; B F Luisi
Journal:  Nucleic Acids Res       Date:  1993-12-11       Impact factor: 16.971

7.  Different activation domains stimulate transcription from remote ('enhancer') and proximal ('promoter') positions.

Authors:  K Seipel; O Georgiev; W Schaffner
Journal:  EMBO J       Date:  1992-12       Impact factor: 11.598

8.  A synergistic increase in potency of a multimerized VP16 transcriptional activation domain.

Authors:  K H Emami; M Carey
Journal:  EMBO J       Date:  1992-12       Impact factor: 11.598

9.  DNA and redox state induced conformational changes in the DNA-binding domain of the Myb oncoprotein.

Authors:  A H Myrset; A Bostad; N Jamin; P N Lirsac; F Toma; O S Gabrielsen
Journal:  EMBO J       Date:  1993-12       Impact factor: 11.598

10.  Functional differences between mammalian transcription activation domains at the yeast GAL1 promoter.

Authors:  M Künzler; G H Braus; O Georgiev; K Seipel; W Schaffner
Journal:  EMBO J       Date:  1994-02-01       Impact factor: 11.598

View more
  12 in total

1.  Differences in determinants required for complex formation and transactivation in related VP16 proteins.

Authors:  M Grapes; P O'Hare
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Effect of promoter strength on protein expression and immunogenicity of an HSV-1 amplicon vector encoding HIV-1 Gag.

Authors:  Kathlyn Santos; Cindy M P Duke; Sol M Rodriguez-Colon; Anthony Dakwar; Shongshan Fan; Michael C Keefer; Howard J Federoff; John G Frelinger; William J Bowers; Stephen Dewhurst
Journal:  Vaccine       Date:  2006-11-15       Impact factor: 3.641

3.  Noninvasive imaging of therapeutic gene expression using a bidirectional transcriptional amplification strategy.

Authors:  Sunetra Ray; Ramasamy Paulmurugan; Manish R Patel; Byeong C Ahn; Lily Wu; Michael Carey; Sanjiv S Gambhir
Journal:  Mol Ther       Date:  2008-09-02       Impact factor: 11.454

4.  The herpesvirus transactivator VP16 mimics a human basic domain leucine zipper protein, luman, in its interaction with HCF.

Authors:  R Lu; P Yang; S Padmakumar; V Misra
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

5.  An activation domain in the C-terminal subunit of HCF-1 is important for transactivation by VP16 and LZIP.

Authors:  Randy L Luciano; Angus C Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-23       Impact factor: 11.205

Review 6.  The PPARα-dependent rodent liver tumor response is not relevant to humans: addressing misconceptions.

Authors:  J Christopher Corton; Jeffrey M Peters; James E Klaunig
Journal:  Arch Toxicol       Date:  2017-12-02       Impact factor: 5.153

7.  Targeted transcriptional activation of silent oct4 pluripotency gene by combining designer TALEs and inhibition of epigenetic modifiers.

Authors:  Sebastian Bultmann; Robert Morbitzer; Christine S Schmidt; Katharina Thanisch; Fabio Spada; Janett Elsaesser; Thomas Lahaye; Heinrich Leonhardt
Journal:  Nucleic Acids Res       Date:  2012-03-02       Impact factor: 16.971

Review 8.  Complexity of Interferon-γ Interactions with HSV-1.

Authors:  Nancy J Bigley
Journal:  Front Immunol       Date:  2014-02-06       Impact factor: 7.561

9.  Direct activation of human and mouse Oct4 genes using engineered TALE and Cas9 transcription factors.

Authors:  Jiabiao Hu; Yong Lei; Wing-Ki Wong; Senquan Liu; Kai-Chuen Lee; Xiangjun He; Wenxing You; Rui Zhou; Jun-Tao Guo; Xiongfong Chen; Xianlu Peng; Hao Sun; He Huang; Hui Zhao; Bo Feng
Journal:  Nucleic Acids Res       Date:  2014-02-05       Impact factor: 16.971

10.  Synchronization of gene expression across eukaryotic communities through chemical rhythms.

Authors:  Sara Pérez-García; Mario García-Navarrete; Diego Ruiz-Sanchis; Cristina Prieto-Navarro; Merisa Avdovic; Ornella Pucciariello; Krzysztof Wabnik
Journal:  Nat Commun       Date:  2021-06-29       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.